TReatment of Pulmonary Hypertension Group II Study

Inclusion Criteria:

- Written informed consent to participate in the study obtained from the patient,
according to local regulations, prior to initiation of any study mandated procedure.

- Male or female, ≥ 18 years of age at the time of screening

- Patient with known pulmonary hypertension (PH) due to left heart disease (WHO Group
II) diagnosed as either HFpEF or HFrEF at chronic state receiving stable guideline
directed medical therapy.

- Combined post-capillary and precapillary pulmonary hypertension diagnosis confirmed by
hemodynamic evaluation performed prior to screening or during baseline (Eligibility II
visit) procedure

- Patient with a current diagnosis of NYHA functional class II/III

- Patient with eGFR levels of ≥ 30 ml/min/1.73m2or serum creatinine levels of ˂
150μmol/l

Exclusion Criteria:

- Pregnant women or women planning a pregnancy within 12 months of study enrolment

- Patient with significant co-morbid condition(s) which, at the discretion of the PI,
are deemed to prohibit study entry

- Patient with life expectancy of less than a year

- Concurrent enrollment in another device or drug trial except for observational studies
(unless specifically approved by the sponsor)

- Patient with pulmonary artery anatomy that precludes treatment

- Patient with moderate to severe pulmonary artery stenosis

- Patient with any pulmonary artery aneurysm

- Patient who has experienced a myocardial infarction, unstable angina pectoris, or a
cerebrovascular accident in the previous 6 months

- Patient experiencing a current episode of acute decompensated heart failure

- Patient who has cardiac pacemakers/ICD/CRT-D that were implanted fewer than three
months prior to enrolment. Patient who has implantable Cardiomems device,
neurostimulators or drug infusion devices, regardless of implant date.